Leal Therapeutics
Develops neuro-metabolic therapeutics for schizophrenia and ALS
$30MSeries A
Role not disclosedEC
Euclidean Capital
Activity from announced rounds
Activity in this selectionUnited States · Aug 31, 2026 · Aug 1, 2026
Euclidean Capital is the investor identified in Circle Pharma’s issuer announcement and by transaction counsel for InduPro.
Recorded funding activity
Circle Pharma develops macrocycle medicines using computational and structure-based methods. The recorded history also includes Savvy Wealth’s operating tools and investment support for financial advisors. Multiple Savvy entries remain separate events pending their own event-level review.
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $107M 2 disclosed · full round size, not this investor’s share